Why is Mankind Pharma Ltd falling/rising?

Recent Price Performance and Market Context

The stock has outperformed its sector and benchmark indices in the short term, delivering a 4.95% gain over the past week compared to the Sensex’s marginal decline of 0.30%. Year-to-date, the stock has similarly outpaced the benchmark with a 4.95% rise. This positive momentum is further underscored by the stock’s consecutive gains over the last two days, accumulating a 5.09% return during this period. Intraday, Mankind Pharma touched a high of Rs 2,320.45, marking a 3.51% increase, signalling strong buying interest.

Technical indicators show the stock trading above its 5-day, 20-day, and 50-day moving averages, which often suggests short-term bullishness. However, it remains below its 100-day and 200-day moving averages, indicating that longer-term trends may still be under pressure. The stock’s liquidity remains adequate, with a trade size capacity of approximately Rs 0.81 crore based on recent average volumes.

Investor Participation and Institutional Confidence

One of the key drivers behind the recent price rise is the surge in investor participation. Delivery volumes on 06 Jan rose sharply by 79.24% to 1.79 lakh shares compared to the five-day average, reflecting increased confidence among market participants. Additionally, institutional investors hold a significant 24.76% stake in the company. These investors typically possess greater analytical resources and tend to back companies with sound fundamentals, lending credibility to the recent price strength.

Financial Efficiency and Debt Management

Mankind Pharma’s management efficiency remains a strong point, with a return on capital employed (ROCE) of 25.78%, indicating effective utilisation of capital to generate profits. The company also maintains a conservative debt profile, with a low Debt to EBITDA ratio of 0.54 times, suggesting a robust ability to service its debt obligations. These factors contribute positively to investor sentiment and support the stock’s recent gains.

Challenges in Profitability and Valuation

Despite these positives, the company’s recent financial results present a mixed picture. The latest nine-month interest expense surged by 122.24% to Rs 530.87 crore, which could weigh on profitability. Meanwhile, the profit after tax (PAT) for the latest six months declined by 20.05% to Rs 949.83 crore. The half-year ROCE also dropped to 12.33%, significantly lower than the annual figure, signalling some operational pressures.

Valuation concerns persist as well. With a ROCE of 11.7 and an enterprise value to capital employed ratio of 4.9, Mankind Pharma is trading at a premium relative to its peers’ historical averages. This expensive valuation is notable given the stock’s underperformance over the past year, where it has delivered a negative return of 21.02%, while the Sensex gained 8.65%. Profit declines of 17.2% over the same period further highlight the challenges the company faces in sustaining growth.

Long-Term Performance and Outlook

Over the longer term, Mankind Pharma’s performance has been below par. The stock has underperformed the BSE500 index over the last three years, one year, and three months. This underperformance, combined with recent flat results and valuation concerns, suggests that while short-term trading activity and investor interest have driven recent gains, fundamental challenges remain.

In summary, Mankind Pharma’s recent price rise on 07-Jan is primarily driven by short-term positive momentum, increased investor participation, and strong management efficiency. However, investors should remain cautious given the company’s recent profit declines, elevated interest costs, and premium valuation compared to peers. The stock’s ability to sustain gains will likely depend on its capacity to improve profitability and justify its valuation in the coming quarters.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →